Palomba, Stefano <br/><br/>
BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial.  [electronic resource] 

 -  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA  Aug 2005 
 - 943-52 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0937-941X 
<br/><br/><label>Standard No.: </label>10.1007/s00198-004-1800-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Aged<br/>Alendronate--administration & dosage<br/>Bone Density--drug effects<br/>Bone Density Conservation Agents--administration & dosage<br/>Bone Resorption--prevention & control<br/>Drug Combinations<br/>Drug Therapy, Combination<br/>Estrogens, Conjugated (USP)--administration & dosage<br/>Female<br/>Genotype<br/>Hormone Replacement Therapy--adverse effects<br/>Humans<br/>Medroxyprogesterone Acetate--administration & dosage<br/>Middle Aged<br/>Osteoporosis, Postmenopausal--drug therapy<br/>Prospective Studies<br/>Raloxifene Hydrochloride--administration & dosage<br/>Receptors, Calcitriol--genetics<br/>Selective Estrogen Receptor Modulators--administration & dosage<br/>Treatment Outcome